A nonaggregating synthetic IAPP, pramlintide, is reported to improve cognition in AD patients and reduce Aβ and phospho-Tau load in the cortex and hippocampus of 5XFAD transgenic mice [28,29]. The gene discussed is MAPT; the disease is Alzheimer disease.